Donald Trump's tariff tussle: Duties on Indian pharma would be 'counterproductive’; America may take at least 3 years to match India’s scale, says Pharmexcil

Despite increased tariffs on Indian imports, the US has temporarily exempted the pharmaceutical sector, recognizing India's critical role in supplying affordable medicines. Pharmexcil emphasizes that tariffs on Indian pharma would harm American consumers, as Indian companies produce low-cost generics. India supplies over 40% of US generic medicines, maintaining high quality standards with numerous FDA-approved facilities.